北京招聘

Major Responsibilities and Duties：

1. Support department head over management team approved business strategies relating to finance and tax in the beginning.

2. Support finance and tax related cross-function business matters.

3. Familiar with company’s current and future business strategy in order to minimize global tax risk and related internal control matter.

Qualifications:

1. Have the hands-on mentality and willing to roll up the sleeves to execute the work in addition to be able to self-manage and motivated mid-level professional.

2. Able to demonstrate the ability to identify issues and bring solutions for the management team.

3. Minimum 6 - 8 years combined experience in public accounting and/ or private company with biopharma related industry or experience is preferred.

4. Big 4 accounting firm experience is preferred.

5. Strong PRC tax technical knowledge and good sense of the international tax environment and the ability to coordinate planning strategy is preferred.

6. Strong sense of accounting knowledge and able to work with finance department for company’s financial statements related tasks.

7. Knowledge of US GAAP and ASC 740 is preferred.

8. Self-motivated and can demonstrate good managerial skill to identify issues and provide suggestive solutions.

9. A team player with vision of driving for team success including outgoing personality willing to lead cross-function projects and tasks.

10. Strong English communication skill in verbal and writing as well as PPT power point preparation.

11. A good personal presentation in business appearance and inter-personal communication skill is essential.

12. PRC CPA a must or
    foreign equivalent professional credential.

天境生物科技(上海)有限公司
天境生物由臧敬五博士领衔的创新药资深研发团队创建，是一家聚焦在肿瘤免疫和自身免疫疾病精准医疗领域的新药研发生物医药科技公司。
公司的核心竞争力在于早期研发、靶点发现和验证、工艺开发&临床前评价、质量科学&质量管理、早期临床研究的能力（包括临床一期和临床二期）。团队在创新药物靶点生物学、创新抗体药物分子结构研发以及创新药物的转化医学及临床研究方面的优势为公司建立一条具有国际竞争力的项目管线创造了基础。公司目前创新药管线含12个在研创新抗体药物项目。领先的创新药项目将在2017年3月申报临床研究并在台湾, 韩国及中国启动临床研究, 其它项目均已进入细胞株或工艺开发阶段。
公司从成立以来已经建立了广泛深入的国际合作, 如与瑞士FERRING公司合作独家引进开发Olamkicept。公司自主研发的全球创新药项目将在2018年进入中国及美国临床研究申报环节并计划在两地启动一期临床研究。